Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 7/20 | 0.49 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052938 | 0.93 | TRPC5 (0.42) | TRPC5TRPC4KCNH2TRPC1TP53 | |
| SCHEMBL19374965 | 0.93 | ADORA3 (0.51) | TRPC5TRPC4KCNH2TRPC1ADORA3 | |
| SCHEMBL16076186 | 0.92 | MAPT (0.43) | TRPC5TRPC4KCNH2ADORA3CYP1A2 | |
| SCHEMBL19505597 | 0.87 | SMN1; SMN2 (0.38) | TRPC5TRPC4KCNH2TRPC1TP53 | |
| SCHEMBL31052954 | 0.86 | P2RX3 (0.42) | TP53P2RX3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31052942 | 0.84 | LMNA (0.49) | TRPC5TRPC4KCNH2TRPC1TP53 | |
| SCHEMBL16076175 | 0.84 | ADORA3 (0.50) | ADORA3CYP1A2CYP2C19 | |
| SCHEMBL16028059 | 0.83 | TRPC5 (0.54) | TRPC5TRPC4KCNH2TRPC1TP53 | |
| SCHEMBL16028356 | 0.83 | TRPC5 (0.54) | TRPC5TRPC4KCNH2TRPC1TP53 | |
| SCHEMBL16028981 | 0.80 | ADORA3 (0.40) | ADORA3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2970303-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885KCNH2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.